STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2024

Sep 6, 2024

==> picture [144 x 47] intentionally omitted <==

September 6, 2024

BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex Dalal Street, Mumbai – 400 001 Bandra (E) Mumbai - 400 051 Scrip code: 532531 Scrip code: STAR

Dear Madam/ Sir,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

“Strides receive USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg”

Thanks & Regards,

For Strides Pharma Science Limited,

MANJULA Digitally signed by MANJULA R R Date: 2024.09.06 09:58:37 +05'30'

Manjula Ramamurthy Company Secretary ICSI Membership No. A30515

Encl. As above

==> picture [505 x 51] intentionally omitted <==

Press Release September 6, 2024

==> picture [132 x 51] intentionally omitted <==

Strides receive USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg

• Strides is the “first approved applicant” and is eligible for 180 days of Competitive Generic Therapy (CGT) exclusivity for Theophylline Extended-Release Tablets, 300 mg

Bangalore, India, September 6, 2024 - Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for the generic version of Theophylline Extended-Release Tablets, 300 mg and 450 mg, from the United States Food & Drug Administration (USFDA).

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), THEO-DUR®, of Schering Corp. Theophylline extended-release tablets are indicated for the treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.

Theophylline Extended-Release Tablets, 300 mg and 450 mg have a combined market size of ~US$ 11.5 mn, with the 300 mg dosage contributing ~US$ 10.8 mn as per IQVIA. The Theophylline Extended-Release Tablets, 300 mg and 450 mg will be manufactured at the company’s flagship facility in KRS Gardens in Bangalore, India.

About Theophylline

Theophylline Extended-Release Tablets (300 mg and 450 mg) are used to manage respiratory conditions like chronic asthma, chronic obstructive pulmonary disease (COPD), and bronchospasm. The medication works as a bronchodilator, relaxing the muscles around the bronchial tubes to ease breathing. It is particularly helpful in preventing and treating symptoms such as wheezing, shortness of breath, and chest tightness. The extended-release formulation allows for prolonged drug release, reducing the frequency of dosing and providing consistent relief from symptoms over time.

About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donorfunded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com.

For further information, please contact:

Institutional Investors Vikesh Kumar Group CFO investor-relations@strides.com Saurabh Ambaselkar Investor Relations +91 99609 31220 saurabh.ambaselkar@strides.com Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560076		Corporate Communication Pallavi Panchmatia:+91 80 6784 0193 Pallavi.panchmatia@strides.com PR Consultancy Adfactors PR Janhavi Bellare: +91 93228 54508 Janhavi.bellare@adfactorspr.com Talal Syed:+91 99876 19679 syed.talal@adfactorspr.com